Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Key Takeaways New data show that GLP1-RA meds like semaglutide can help slow the progression of chronic kidney diseaseThe ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.